Comparison

PKI 14-22 amide,myristoylated (TFA) European Partner

Item no. HY-P1291A-5mg
Manufacturer MedChem Express
Amount 5 mg
Quantity options 10 mg 1 mg 5 mg
Category
Type Peptides
Specific against other
Purity 99.38
Citations [1]L Ydrenius, et al. Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosis. J Leukoc Biol. 2000 Apr;67(4):520-8.|[2]Cheng F, et al. Suppression of Zika Virus Infection and Replication in Endothelial Cells and Astrocytes by PKA Inhibitor PKI 14-22. J Virol. 2018 Jan 30;92(4):e02019-17.|[3]Gabra BH, et al. Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res. 2008 Jun 27;1217:70-7.
Smiles CCCCCCCCCCCCCC(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N[C@H](C(N)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Shipping Condition Cool pack
Available
Manufacturer - Type
Peptides
Manufacturer - Applications
Cancer-Kinase/protease
Manufacturer - Targets
Epigenetic Reader Domain; Flavivirus; PKA
Shipping Temperature
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Molecular Weight
1323.51
Product Description
PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs[1][2][3].
Manufacturer - Research Area
Infection; Neurological Disease
Solubility
H2O: 1.85 mg/mL (ultrasonic)
Manufacturer - Pathway
Anti-infection; Epigenetics; Stem Cell/Wnt; TGF-beta/Smad
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close